Main
>
ONCOLOGY (**)
>
Lymphoma>HL>Classical>R/R ***
>
TREAT.:
>
CN. B. TislelizuMAb
CN. B. TislelizuMAb's subsections
(*) CN Approval Date: 2019. 12.27.
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 4
Patent>UpDate: 2019. 12.31.
Pipeline Web-Site
PR Web-Site
CN. B. TislelizuMAb's products
This section has no products
(*) CN Approval Date: 2019. 12.27.
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 4
Patent>UpDate: 2019. 12.31.
Pipeline Web-Site
PR Web-Site